Company research
ImageneBio, Inc.
CIK 1835579Updated Nov 11, 2026
SecurityIMA · NASDAQ · equity
Name history
Ikena Oncology, Inc. · through Jul 25, 2025
IMA price & chart
Loading TradingView…
NASDAQ:IMA on TradingView ↗About the company
Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company’s program, olevaprubart, is a receptor-targeting, non-depleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of olevaprubart in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of olevaprubart in patients with moderate-to-severe atopic dermatitis. For more information, please visit www.imagenebio.com.
In the news
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York ↗
SEC disclosures
ImageneBio, Inc. IPO declared effective by SEC ↗
Recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
4 filing
EFFECT filing
EFFECT filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 160,878,000Source | 148,988,000Source | 152,045,000Source | 126,166,000Source | 157,485,000Source | 136,682,000Source | 130,838,000Source | 172,782,000Source | 152,976,000Source | 141,510,000Source | 192,092,000Source | 172,259,000Source |
| Property, Plant and Equipment, NetUSD | 1,000Source | 682,000Source | — | 419,000Source | 772,000Source | — | 506,000Source | 864,000Source | 0Source | 593,000Source | 2,335,000Source | 3,205,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 103,162,000Source | 45,190,000Source | 94,677,000Source | 58,290,000Source | 44,268,000Source | 76,048,000Source | 36,763,000Source | 52,852,000Source | 94,532,000Source | 39,393,000Source | 119,894,000Source | 59,919,000Source |
| Assets, CurrentUSD | 147,532,000Source | 141,533,000Source | 141,112,000Source | 99,013,000Source | 149,321,000Source | 122,006,000Source | 116,999,000Source | 161,166,000Source | 140,288,000Source | 127,169,000Source | 178,662,000Source | 160,010,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,949,000Source | 3,500,000Source | 4,959,000Source | 3,371,000Source | 3,902,000Source | 4,798,000Source | 2,948,000Source | 3,817,000Source | 4,939,000Source | 2,783,000Source | 3,197,000Source | 3,063,000Source |
| Operating Lease, Right-of-Use AssetUSD | 884,000Source | 4,160,000Source | 521,000Source | 2,561,000Source | 4,779,000Source | 616,000Source | 3,102,000Source | 5,241,000Source | 790,000Source | 3,635,000Source | 5,686,000Source | 5,255,000Source |
| Other Assets, NoncurrentUSD | 4,952,000Source | — | — | — | — | — | — | — | 4,878,000Source | — | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 21,046,000Source | 14,756,000Source | 9,971,000Source | 10,259,000Source | 14,626,000Source | 13,355,000Source | 12,588,000Source | 17,435,000Source | 19,837,000Source | 15,576,000Source | 22,335,000Source | 25,290,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | — | 48,000Source | — | 48,000Source | 48,000Source | — | 48,000Source | 48,000Source | — | 48,000Source | 48,000Source | 36,000Source |
| Additional Paid in CapitalUSD | 362,870,000Source | 456,439,000Source | 392,964,000Source | 458,799,000Source | 455,422,000Source | 364,005,000Source | 458,341,000Source | 454,143,000Source | 363,094,000Source | 457,437,000Source | 452,142,000Source | 361,915,000Source |
| Retained Earnings (Accumulated Deficit)USD | -223,143,000Source | -322,495,000Source | -250,850,000Source | -343,005,000Source | -312,261,000Source | -240,672,000Source | -340,238,000Source | -298,531,000Source | -230,053,000Source | -331,619,000Source | -282,385,000Source | -214,219,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 94,000Source | 240,000Source | -51,000Source | 65,000Source | -350,000Source | -17,000Source | 99,000Source | -313,000Source | 87,000Source | 68,000Source | -48,000Source | -763,000Source |
| Stockholders' Equity Attributable to ParentUSD | 139,832,000Source | -152,754,000Source | 142,074,000Source | -180,351,000Source | 142,859,000Source | 123,327,000Source | -169,600,000Source | 155,347,000Source | 133,139,000Source | 125,934,000Source | 169,757,000Source | 146,969,000Source |
| Liabilities and EquityUSD | 160,878,000Source | 148,988,000Source | 152,045,000Source | 126,166,000Source | 157,485,000Source | 136,682,000Source | 130,838,000Source | 172,782,000Source | 152,976,000Source | 141,510,000Source | 192,092,000Source | 172,259,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 11,144,000Source | 9,240,000Source | 6,573,000Source | 7,324,000Source | 8,196,000Source | 6,634,000Source | 8,793,000Source | 10,169,000Source | 11,234,000Source | 10,778,000Source | 14,205,000Source | 21,503,000Source |
| Operating Lease, Liability, CurrentUSD | 2,161,000Source | 3,923,000Source | 1,912,000Source | 3,834,000Source | 3,695,000Source | 2,306,000Source | 3,892,000Source | 3,443,000Source | 2,262,000Source | 3,784,000Source | 3,558,000Source | 1,907,000Source |
| Accounts Payable, CurrentUSD | 2,081,000Source | 1,540,000Source | 977,000Source | 512,000Source | 1,408,000Source | 568,000Source | 805,000Source | 1,909,000Source | 1,439,000Source | 897,000Source | 2,066,000Source | 2,093,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,284,000Source | 4,471,000Source | 0Source | 1,843,000Source | 5,397,000Source | 110,000Source | 2,718,000Source | 6,302,000Source | 713,000Source | 3,737,000Source | 7,180,000Source | 3,787,000Source |
| Other Liabilities, NoncurrentUSD | 1,108,000Source | 1,045,000Source | 838,000Source | 1,092,000Source | 1,033,000Source | 881,000Source | 1,077,000Source | 964,000Source | 870,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 136,200,000Source | — | — | 117,200,000Source | — | — | — | — | 175,500,000Source | 156,900,000Source |
| Deferred Revenue, CurrentUSD | 0Source | — | — | — | — | — | — | — | 0Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Preferred Stock, Value, Issued | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -10,619,000Source | -6,077,000Source | -45,349,000Source | -49,234,000Source | -68,166,000Source | -68,765,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 0Source | 2,000Source | 400,000Source | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 876,000Source | 57,000Source | 15,391,000Source | 5,295,000Source | 7,632,000Source | 7,525,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -871,000Source | 1,425,000Source | -2,820,000Source | -1,169,000Source | -2,870,000Source | -291,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -14,800,000Source | -7,230,000Source | -47,844,000Source | -46,004,000Source | -79,743,000Source | -74,109,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -440,000Source | 0Source | -5,814,000Source | -34,903,000Source | 64,144,000Source | -99,284,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | 414,000Source | 1,431,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 663,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -3,244,000Source | 27,000Source | 135,468,000Source | — | 75,980,000Source | 1,095,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -18,484,000Source | -7,200,000Source | 82,414,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 103,162,000Source | 8,731,000Source | 94,677,000Source | 6,021,000Source | 76,048,000Source | 4,918,000Source | 94,532,000Source | 40,265,000Source | 121,172,000Source | 60,791,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 23,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 0Source | 3,000Source | 604,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | 911,000Source | 0Source | 876,000Source | 57,000Source | 15,391,000Source | 5,295,000Source | 7,632,000Source | 7,525,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | 136,200,000Source | — | 117,200,000Source | — | — | — | 175,500,000Source | 156,900,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | -12,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | 87,000Source | — | 490,000Source | 1,020,000Source | 751,000Source |
| Gain (Loss) on Sale of PropertiesUSD | — | — | — | — | — | — | — | — | — | — | -5,000Source | -173,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | 0Source | -99,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 11,036,000Source | 1,651,000Source | 5,115,000Source | 1,705,000Source | 6,118,000Source | 2,755,000Source | 20,726,000Source | 23,679,000Source | 24,925,000Source | 22,201,000Source |
| Income Tax Expense (Benefit)USD | — | — | -74,000Source | 0Source | 16,000Source | 15,000Source | 10,000Source | 28,000Source | -350,000Source | 152,000Source | -162,000Source | 0Source |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | 7,111,000Source | 2,149,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -24,779,000Source | -3,183,000Source | -10,178,000Source | -7,585,000Source | -10,619,000Source | -6,077,000Source | -45,349,000Source | -49,234,000Source | -68,166,000Source | -68,765,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -25,625,000Source | -6,181,000Source | -10,178,000Source | -10,734,000Source | -10,619,000Source | -9,128,000Source | -52,395,000Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 1,741,000Source | -1,147,000Source | 1,622,000Source | -227,000Source | 1,470,000Source | -82,000Source | 2,752,000Source | 9,891,000Source | — | — |
| Operating ExpensesUSD | — | — | 26,594,000Source | 5,536,000Source | 11,784,000Source | 7,358,000Source | 12,079,000Source | 6,795,000Source | 49,251,000Source | 58,973,000Source | 84,577,000Source | 86,522,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | 533,000Source | — | 2,051,000Source | 1,714,000Source | 1,283,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | — | 1,744,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 1,837,000Source | -1,193,000Source | 374,000Source | 9,000Source | 341,000Source | -5,000Source | 717,000Source | 2,518,000Source | 7,089,000Source | 2,139,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | 15,000,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 35,000Source | 45,000Source | 45,000Source | — | 136,000Source | 1,095,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 0Source | 3,500,000Source | — | — | — | — | 800,000Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 3,500,000Source | — | — | — | 800,000Source | 800,000Source | — | 9,160,000Source | 15,618,000Source |
| Operating Income (Loss)USD | — | — | -26,594,000Source | -2,036,000Source | -11,784,000Source | -7,358,000Source | -12,079,000Source | -5,995,000Source | -48,451,000Source | -58,973,000Source | -75,417,000Source | -70,904,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,837,000Source | -1,193,000Source | 374,000Source | 9,000Source | 341,000Source | -5,000Source | 717,000Source | 2,518,000Source | 7,089,000Source | 2,139,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -24,853,000Source | -3,183,000Source | -10,162,000Source | -7,585,000Source | -10,609,000Source | -6,077,000Source | -45,699,000Source | -49,082,000Source | -68,328,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | -74,000Source | 0Source | 16,000Source | 15,000Source | 10,000Source | 28,000Source | -350,000Source | 152,000Source | -162,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -24,779,000Source | -3,183,000Source | -10,178,000Source | -7,585,000Source | -10,619,000Source | -6,077,000Source | -45,349,000Source | -49,234,000Source | -68,166,000Source | -68,765,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -2.91Source | -2.58Source | -0.63Source | -4.46Source | -0.95Source | -3.8Source | -9.64Source | -1.02Source | -1.63Source | -1.9Source |
| Earnings Per Share, DilutedUSD per share | — | — | -2.91Source | -2.58Source | -0.63Source | -4.46Source | -0.95Source | -3.8Source | -9.64Source | -1.02Source | -1.63Source | -1.9Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 8,526,781Source | 1,400,557Source | — | 48,258,111Source | 11,211,268Source | 1,409,963Source | 4,870,906Source | 48,258,111Source | 41,735,081Source | 36,188,420Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | 48,258,111Source | 16,161,721Source | 2,406,516Source | 11,211,268Source | 2,404,832Source | — | 48,258,111Source | 41,735,081Source | 36,188,420Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -350,000Source | 152,000Source | -169,000Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 0Source | 2,000Source | 399,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 11,036,000Source | 1,651,000Source | 5,115,000Source | 1,705,000Source | 6,118,000Source | 2,755,000Source | 20,726,000Source | 23,679,000Source | 24,925,000Source | 22,201,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -34,633,000Source | — | — | — |
| InterestExpenseOperatingUSD | — | — | — | — | — | — | — | — | 489,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | -96,000Source | 46,000Source | 1,248,000Source | -236,000Source | 1,129,000Source | -77,000Source | 2,035,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | 7,111,000Source | 2,149,000Source |
| Investment Income, NetUSD | — | — | — | 1,771,000Source | — | 1,290,000Source | — | 1,418,000Source | — | 7,373,000Source | — | — |
| Labor and Related ExpenseUSD | — | — | 1,046,000Source | 567,000Source | — | — | — | — | 5,182,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -25,625,000Source | -6,181,000Source | -10,178,000Source | -10,734,000Source | -10,619,000Source | -9,128,000Source | -52,395,000Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 1,741,000Source | -1,147,000Source | 1,622,000Source | -227,000Source | 1,470,000Source | -82,000Source | 2,752,000Source | 9,891,000Source | — | — |
| Operating ExpensesUSD | — | — | 26,594,000Source | 5,536,000Source | 11,784,000Source | 7,358,000Source | 12,079,000Source | 6,795,000Source | 49,251,000Source | 58,973,000Source | 84,577,000Source | 86,522,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | 533,000Source | — | 2,051,000Source | 1,714,000Source | 1,283,000Source |
| Other General and Administrative ExpenseUSD | — | — | 2,849,000Source | 415,000Source | — | — | — | — | 4,188,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 15,558,000Source | 3,885,000Source | 6,669,000Source | 5,653,000Source | 5,961,000Source | 4,040,000Source | 28,525,000Source | 30,875,000Source | 59,652,000Source | 64,321,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 0Source | 3,500,000Source | — | — | — | — | 800,000Source | — | — | — |
Offerings
Registration 333-290108
Registration 333-298002
Registration 333-298008
Filing attachments
d139863dex991.htm · 8-K · 2026-11-09
Exhibit 99.1 ImageneBio Reports Third Quarter 2026 Financial Results SAN DIEGO, November 9, 2026 - ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the quarter ended September 30, 2026, and provided a company update. Company Highlights Olevaprubart, also known as IMG-007, a potential first-in-class therapeutic targeting the OX40 pathway, is a non-T cell-depleting, ADCC-silenced, anti-OX40 receptor antagonist with an extended half-life. ───…
Read attachment ↗d150354dex411.htm · S-3 · 2026-08-05
Exhibit 4.11 I MAGENE B IO, I NC. AND _____________, A S W ARRANT A GENT F ORM OF D EBT S ECURITIES W ARRANT A GREEMENT D ATED A S O F __________ I MAGENE B IO, I NC. F ORM OF D EBT S ECURITIES W ARRANT A GREEMENT T HIS D EBT S ECURITIES W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between I MAGENE B IO, I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate tru…
Read attachment ↗d150354dex412.htm · S-3 · 2026-08-05
Exhibit 4.12 IMAGENEBIO, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20__ Debt Securities T ABLE O F C ONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 …
Read attachment ↗d150354dex48.htm · S-3 · 2026-08-05
Exhibit 4.8 I MAGENE B IO, I NC. AND _____________, A S W ARRANT A GENT F ORM OF C OMMON S TOCK W ARRANT A GREEMENT D ATED A S O F __________ I MAGENE B IO, I NC. F ORM OF C OMMON S TOCK W ARRANT A GREEMENT T HIS C OMMON S TOCK W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between I MAGENE B IO, I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office …
Read attachment ↗d150354dex49.htm · S-3 · 2026-08-05
Exhibit 4.9 I MAGENE B IO, I NC. AND _____________, A S W ARRANT A GENT F ORM OF P REFERRED S TOCK W ARRANT A GREEMENT D ATED A S O F __________ I MAGENE B IO, I NC. F ORM OF P REFERRED S TOCK W ARRANT A GREEMENT T HIS P REFERRED S TOCK W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between I MAGENE B IO, I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trus…
Read attachment ↗d166048dex991.htm · 8-K · 2026-08-05
EX-99.1 2 d166048dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 ImageneBio Reports Second Quarter 2026 Financial Results SAN DIEGO, Aug. 5, 2026 (GLOBE NEWSWIRE) - ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the quarter ended June 30, 2026, and provided a company update. Company Highlights Olevaprubart, also known as IMG-007, the potential first-in-class therapeutic targeting the OX40 pathway, is a non-T cell-depleting, ADCC-silenced, anti…
Read attachment ↗